Chevy Chase Trust Holdings LLC Buys 56,853 Shares of Natera, Inc. (NASDAQ:NTRA)

Chevy Chase Trust Holdings LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 13.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 480,742 shares of the medical research company’s stock after acquiring an additional 56,853 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.36% of Natera worth $61,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Covestor Ltd grew its holdings in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. GAMMA Investing LLC boosted its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the period. CIBC Asset Management Inc grew its holdings in Natera by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after acquiring an additional 111 shares during the last quarter. RiverPark Advisors LLC increased its position in shares of Natera by 3.5% in the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock valued at $425,000 after acquiring an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC raised its stake in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now owns 185,034 shares in the company, valued at approximately $27,090,827.94. This represents a 2.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 9,682 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the sale, the director now directly owns 9,704 shares in the company, valued at approximately $1,552,445.92. The trade was a 49.94 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,503 shares of company stock valued at $6,325,804. Corporate insiders own 7.60% of the company’s stock.

Natera Stock Down 0.4 %

NTRA stock opened at $167.78 on Monday. The business has a 50 day moving average of $135.51 and a 200 day moving average of $120.41. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $22.15 billion, a PE ratio of -95.33 and a beta of 1.53. Natera, Inc. has a twelve month low of $55.56 and a twelve month high of $171.95.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the business earned ($0.95) EPS. Natera’s revenue was up 63.9% compared to the same quarter last year. On average, research analysts forecast that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the topic of several recent analyst reports. Craig Hallum raised their target price on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. boosted their target price on Natera from $135.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. BTIG Research raised their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group reduced their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.